Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, has announced a partnership with Massachusetts General Hospital (Mass General). Mass General will serve as…
Mettler-Toledo International Inc. (NYSE: MTD) has released its financial results for the second quarter of 2024. Key highlights include: Second Quarter Highlights Management Commentary Patrick Kaltenbach, President and CEO, commented, “Our team delivered strong Laboratory sales growth in Europe and…
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) has announced that the European Commission has granted Orphan Drug Designation to AMX0035, its proprietary fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO), for treating Wolfram syndrome. This designation follows a positive opinion from…
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company specializing in innovative treatments for neurological diseases, has announced the grant of inducement awards to two new employees. The Compensation Committee of Longboard’s Board of Directors approved non-qualified stock options to…
DocGo Inc. (Nasdaq: DCGO), a leader in technology-enabled mobile health services, has announced that its subsidiary, Exceptional Medical Transportation, has been granted a one-year, $4 million contract extension. This extension will see Exceptional Medical Transportation continue to provide 911 basic…
Agilent Technologies Inc. (NYSE: A) has announced FDA approval for its MAGE-A4 IHC 1F9 pharmDx (SK032) as a diagnostic tool to identify patients with synovial sarcoma who may qualify for TECELRA® (afamitresgene autoleucel, or afami-cel), a MAGE-A4-directed engineered TCR T-Cell…
VBI Vaccines Inc. (Nasdaq: VBIV) has provided an update on its restructuring proceedings, initially announced on July 30, 2024. U.S. Chapter 15 Filing:On August 2, 2024, the U.S. Bankruptcy Court for the District of Delaware granted provisional relief under Chapter…
Owens & Minor, Inc. (NYSE: OMI) Announces Second Quarter Financial Results for 2024 Owens & Minor, Inc. (NYSE: OMI) has released its financial results for the second quarter ending June 30, 2024. Key Highlights: Edward A. Pesicka, President & CEO,…
BostonGene, a leader in AI-driven molecular and immune profiling solutions, has announced a new research collaboration with Takeda focused on immuno-oncology. This partnership aims to enhance clinical solutions and patient outcomes by pinpointing key molecular drivers and predictive markers of…
Twist Bioscience Corporation (NASDAQ: TWST), known for its high-quality synthetic DNA via its silicon platform, has reported its financial results and business highlights for the third quarter of fiscal 2024, ending June 30, 2024. Financial Performance Business Highlights Emily M.…
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced that the U.S. FDA has granted accelerated approval for TECELRA® (afamitresgene autoleucel) as the first engineered cell therapy for treating solid tumors. This approval is specifically for adults with unresectable or metastatic synovial…
VSee Health, Inc. (Nasdaq: VSEE), known for its telehealth services that optimize workflows and improve patient care, has partnered with Ava Robotics, a leader in intelligent workplace robots. Together, they will develop telepresence solutions for the inpatient ICU market, including…